News|Articles|November 19, 2026

Gut Microbiome Emerging as a Modifiable Target in Stroke Risk and Recovery

Author(s)Marco Meglio
Listen
0:00 / 0:00

Key Takeaways

  • Unexplained residual stroke risk may be substantially mediated by microbiome-derived metabolites that influence atherogenesis, systemic inflammation, and cholesterol homeostasis beyond traditional vascular risk factor control.
  • Modifying microbiome composition is comparatively accessible via dietary fiber manipulation, calorie restriction, prebiotics, probiotics, and fecal microbiota transplant, creating multiple prevention-oriented intervention paths.
SHOW MORE

William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.

The 2026 Society of Vascular and Interventional Neurology (SVIN) Annual Meeting, held in Las Vegas, Nevada, marked the society’s 20th annual gathering under the chair’s theme “SVIN 2026: All In!” The meeting brought together researchers, practitioners, and industry leaders in vascular and interventional neurology, with a program of keynote lectures, interactive workshops, and poster presentations centered on advances in stroke and neurointervention.

Among the sessions was a presentation titled “Microbiome and Vascular Implications,” which examined how the trillions of organisms in the gut may influence atherosclerotic disease and stroke through the metabolites they produce. Interest in the gut-brain connection has grown as clinicians look beyond traditional vascular risk factors to explain the residual risk that remains in many patients, along with potential approaches to modify the microbiome, from diet and prebiotics to probiotics and fecal transplant.

NeurologyLive® sat down with William Roth, MD, assistant professor of neurology at the University of Chicago, who delivered the presentation, to discuss the topic in more depth. Roth answered questions on the central takeaways from his talk and why the microbiome is gaining traction in stroke research. He also covered how stroke itself alters the gut, which strategies could realistically be used in the acute window, and where the field should focus next.

NeurologyLive: For those who may not have had a chance to attend, can you give an idea of what you talked about and why this topic is of interest to you?

William Roth, MD: Part of this talk was to educate everyone that this topic has been around for as long as antiquity. Anatomists, shamans, and all sorts of thinkers dating back thousands of years have been thinking about the gut-brain connection. What we now understand is that the gut is composed of trillions of organisms that have a lot of different behaviors, especially with respect to disease, including atherosclerosis. My talk focused on helping people who don’t live in the space and work with the microbiome routinely understand some of the main takeaways from that work. That’s largely focused on the risk that certain metabolites confer to the risk of atherosclerotic disease.

Focusing on the stroke field specifically, why do you think this topic has gained more traction and attention in the last couple of years?

One major factor is that we still don’t prevent all strokes, even though we have identified many of the main traditional vascular risk factors and have ways to treat them. People still develop worsening carotid plaque and go on to have strokes. The traditional risk factors explain only about 20% or so of the variability of plaque size. There is a lot of residual risk that is unexplained, and I think in that world the microbiome is probably a major player. Some of the research coming out suggests that much of that residual risk, and even the risk from the traditional vascular risk factors, is heavily influenced by the microbiome.

What’s also interesting about the gut microbiome is that there are a lot of ways you can change it. It’s a vital organ, but you don’t need transplant surgery to transplant the organ. You can change it in many different ways, and some of those are relatively easy to do. By changing your diet, the nutrients, and the fiber content, and through other strategies such as calorie restriction, you can beneficially change the composition of the microbiome. By changing the microbiome, you change a lot of upstream factors, like systemic inflammation and cholesterol homeostasis, along with other things known to exacerbate disease.

Diet is not the only option. Fecal transplant is one option, as are probiotics, which are encapsulated organisms, and prebiotics, which are fiber products that can help cultivate a healthier microbiome. There are lots of different strategies we can implement to change the microbiome to help prevent stroke or serve other beneficial needs.

Stroke itself seems to alter the gut microbiome, which may in turn affect recovery. How do you think about that two-way relationship between the brain and the gut?

It’s very complex. We know that people who have strokes develop dysbiosis, a state of the gut microbiome characterized by lower diversity and a greater preponderance of pathogens, or organisms that we think are more proinflammatory and more injurious to health. Understanding how the microbiome changes dynamically throughout the natural history of stroke is a very interesting future research topic.

In my talk, I discussed how the gut microbiome might influence stroke risk. But we also know that in the immediate aftermath of a stroke, there is a lot of inflammation and many downstream effects on the rest of the body. Seeing how the stroke affects the gut dynamically during that acute window is also interesting. We may be able to find ways to modify the microbiome in that window to help prevent some of the downstream effects that can lead to worse neurologic recovery.

What has the field been discussing in terms of potential strategies for that short acute window, and what could realistically work in a clinical care setting?

That’s a great question, because the treatment options for altering the microbiome have to fit the time frame you are trying to treat. If you are trying to prevent stroke-induced inflammation or some of the dangerous inflammatory or redox mechanisms involved in brain injury after a stroke, you can’t just give a probiotic for 6 weeks. You need something that is going to happen right now. One interesting line of inquiry is gut decontamination, in which you presume that a cohort of patients has a dysbiotic microbiome and you eliminate it with antibiotics.

There was recently a trial in traumatic brain injury where patients were given a single dose of an antibiotic, and it conferred a mortality benefit, which was very surprising. The idea was that it was preventing ventilator-associated pneumonia in patients with traumatic brain injury, but a lot of us wondered if it was also decontaminating a dangerous microbiome that would otherwise exacerbate acute brain injury. Early feeding enriched in certain prebiotics that can help cultivate a healthier microbiome might also be helpful during a short hospital stay. There are a lot of different options.

I think it’s also likely that, by understanding the microbiome and the metabolome and how they interact with disease, especially after stroke or other forms of acute brain injury, we may be led to different therapeutic routes that don’t necessarily alter the microbiome but help us identify beneficial metabolites that can prevent inflammation early on. We may not even have to touch the gut. From what we learn from the gut, we might give a short-chain fatty acid, for example, that helps in the long term. We don’t know yet, but there are certainly a lot of options and a lot of interesting work being done in the acute setting to help us better understand it.

Where does the clinical community need to spend more time and effort to further our understanding of the role of the gut microbiome in stroke?

I think first is awareness. We don’t routinely check a lab that tells us our microbiome composition, so it doesn’t occupy much of our mind share as clinicians. We don’t know exactly what to measure, and when we do, it takes a long time to get the results back, so we don’t have clinically actionable feedback. Having interviews like this, letting clinicians know that this is being actively researched, matters. It should be on your mind when you are thinking about delivering antibiotics or what kind of diet to recommend for patients. Increasing awareness will generate more interest in the stroke community.

What we need to understand the microbiome is data. We need all the clinical data that comes with performing clinical research, but we also need to measure the microbiome with samples, such as stool samples and rectal swabs, and other ways to look at circulating metabolites that are known to be modified by the microbiome.

Transcript was edited for clarity. For more SVIN 2026 coverage, click here.


Related to this article